Pathogenetic justification of possibility of antidiuretic hormone use in incontinent women
- Authors: Osipova N.A.1, Niauri D.A.1, Gzgzyan A.M.1
-
Affiliations:
- St Petersburg State University
- Issue: Vol 66, No 4 (2017)
- Pages: 68-78
- Section: Articles
- URL: https://journals.rcsi.science/jowd/article/view/6921
- DOI: https://doi.org/10.17816/JOWD66468-78
- ID: 6921
Cite item
Full Text
Abstract
Hypothesis/aims of study. Urine incontinence seems to include several pathogenetic forms, as efficient therapy is provided by different medications. Commonly used in the treatment of female patients with overactive bladder and nocturnal polyuria is desmopressin which normalizes the water excretion of the kidney, which is disturbed by a presumed inverted rhythm of vasopressin secretion in these patients. The current analysis was undertaken to evaluate the clinical efficiency of desmopressine in incontinent patients with nocturnal polyuria and polyuria.
Study design, materials and methods. A total of 84 patients with complaints of urinary incontinence, polyuria (24-urine volume of 40 mL/kg bodyweight or above) or nocturnal polyuria (nocturnal volume/24-h urine volume of 0.33 or above) and 14 control subjects were included. Mean patient age was 43.6 ± 4.6 years, in control subjects 38.5 ± 6.4 (p > 0.05). All participants performed 24h-urinecollection to determine the voided volumes and the levels of creatinine, osmolality, sodium, magnesium and potassium for each sample. A blood sample was taken during the 24-urinecollection to determine the levels of creatinine, osmolality, sodium, magnesium and potassium. The examination of patients with polyuria and nocturnal polyuria was performed twice: in the initial state and one month after the start of treatment with optimal dose of desmopressin. Optimal dose was established through an open-label dose-titration using 0.1 mg, 0.2 mg and 0.4 mg of desmopressin (Minirin). Safety parameters assessed included incidence of adverse events, vital signs and serum sodium levels.
Results. In patients with polyuria and nocturnal polyuria the glomerular filtration rate was normal, whereas diuresis and solute (sodium, magnesium, potassium) excretion in night samples in nocturnal polyuria and both in night and day samples in polyuria were increased. The higher diuresis and the higher solute excretion observed in nocturnal polyuria and polyuria are accompanied by an increase of free water reabsorption. In nocturnal polyuria and polyuria a high correlation was found between the free water reabsorption and solute excretion. This occurs against the background of the high night and day osmotic concentration. The statistically significant recovery of renal function occurred in 12 incontinent women with polyuria and 18 with nocturnal polyuria. In these papients there was a statistically significant decrease in diuresis, osmolar clearance and excretion of sodium, potassium and magnesium.
Concluding message. As desmopressin affects cells of the thick ascending limb of Henle’s loop, it is likely that nocturnal polyuria and polyuria result from a disturbed regulation of the function of these cells. Normalization can be achieved by desmopressin administration to stimulate V2-receptors, which increase water permeability and water reabsoption in collecting ducts as well as ion reabsorption by cells of the thick ascending limb of Henle’s loop.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Natalia A. Osipova
St Petersburg State University
Author for correspondence.
Email: naosipova@mail.ru
Assistant of the Department of Obstetrics, Gynecology and Reproduction
Russian Federation, 7/9, Universitetskaya nab., St.Petersburg, 199034Dariko A. Niauri
St Petersburg State University
Email: d.niauri@mail.ru
Doctor of Medical Sciences, Head of the Department of Obstetrics, Gynecology and Reproduction
Russian Federation, 7/9, Universitetskaya nab., St.Petersburg, 199034Alexander M. Gzgzyan
St Petersburg State University
Email: d.niauri@mail.ru
Doctor of Medical Sciences, Professor of the Department of Obstetrics, Gynecology and Reproduction
Russian Federation, 7/9, Universitetskaya nab., St.Petersburg, 199034References
- Аполихина И.А., Ромих В.В., Андикян В.М. Совре менные принципы консервативного лечения недержания мочи у женщин // Урология. – 2005. – № 5. – С. 72–75. [Apolihina IA, Romih VV, Andikjan VM. [The modern principles of conservative treatment of urine incontience in women. Urologiia. 2005;(5):72-75. (In Russ.)]
- Балан В.Е., Анкирская А.С., Есесидзе З.Т., и др. Патогенез атрофического цистоуретрита и различные виды недержания мочи у женщин в климактерии // Consilium medicum. – 2001. – Т. 3. – № 7. – С. 326–331. [Balan VE, Ankirskaja AS, Esesidze ZT, et al. [Pathogenesis of an atrophic cystoureteritis and different types of urine incontience in climacteric women. Consilium medicum. 2001;3(7):326-331. (In Russ.)]
- Борисов И.А., Перов Ю.Л. Старческая почка / Тареева И.Е. (ред.) Нефрология. – М., 2001. – С. 509–525. [Borisov IA, Perov JuL. Starcheskaja pochka. Ed. by Tareeva IE. Nefrologija. Moscow; 2001. P. 509-25. (In Russ.)]
- Гончаревская О.А., Наточин Ю.В. Простагландин Е2 угнетает реабсорбцию магния в начальном отделе дистального отдела нефрона тритона // Докл. РАН. – 1994. – Т. 337. – № 1. – С. 125–127. [Goncharevskaja OA, Natochin JuV. Prostaglandin E2 ugnetaet reabsorbciju magnija v nachal’nom otdele distal’nogo otdela nefrona tritona. Dokl. RAN. 1994;337(1):125-7. (In Russ.)]
- Иванова Л.H. Вазопрессин: клеточные и молекулярные аспекты его антидиуретического действии // Вест. РАМН. – 1999. – № 3. – С. 40–45. [Ivanova LH. Vazopressin: kletochnye i molekuljarnye aspekty ego antidiureticheskogo dejstvija. Vest RAMN. 1999;(3):40-5. (In Russ.)]
- Мазо Е.Б. Медикаментозное лечение гиперактивного мочевого пузыря // Русский медицинский журнал. – 2004. – Т. 12. – № 8. – С. 522–526. [Mazo EB. Medikamentoznoe lechenie giperaktivnogo moche vogo puzyrja. Russkij medicinskij zhurnal. 2004;12(8): 522-6. (In Russ.)]
- Наточин Ю.В. Физиология почки: формулы и расчеты. – Л.: Наука, 1974. [Natochin JuV. Fiziologija pochki: formuly i raschety. Leningrad: Nauka; 1974. (In Russ.)]
- Наточин Ю.В. Физиология водно-солевого обмена и почки. – СПб., 1993. [Natochin JuV. Fiziologija vodno-solevogo obmena i pochki. Saint Petersburg; 1993. (In Russ.)]
- Неймарк А.И., Раздорская М.В. Актуальные проблемы урогинекологии. Недержание мочи у женщин // Акушерство, гинекология и репродукция. – 2011. – Т. 5. – № 4. – С. 27–34. [Nejmark AI, Razdorskaja MV. Topical problems in urogynaecology. Urinary incontinence in women. Akusherstvo, ginekologija i reprodukcija. 2011;5(4):27-34. (In Russ.)]
- Осипова Н.А., Гулиев Б.Г., Ниаури Д.А., Гзгзян А.М. Осморегулирующая функция почек при различных типах недержания мочи у женщин // Экспериментальная и клиническая урология. – 2016. – № 3. – С. 144–149. [Osipova NA, Guliev BG, Niauri DA, Gzgzjan AM. Osmoregulirujushhaja funkcija pochek pri razlichnyh tipah nederzhanija mochi u zhenshhin. Jeksperimental’naja i klinicheskaja urologija. 2016;(3):144-9. (In Russ.)]
- Осипова Н.А., Ниаури Д.А., Зиятдинова Г.М. Суточный ритм мочеобразования и мочеотделения при недержании мочи у женщин // Гинекология. – 2015. – № 2. – С. 74–76. [Osipova NA, Niauri DA, Zijatdinova GM. Sutochnyj ritm mocheobrazovanija i mocheotdelenija pri nederzhanii mochi u zhenshhin. Ginekologija. 2015;(2):74-6. (In Russ.)]
- Осипова Н.А., Ниуари Д.А., Гзгзян А.М. Ионорегулирующая функция почек при различных типах недержания мочи у женщин // Журнал акушерства и женских болезней. – 2016. – Т. 65. – № 2. – С. 44–53. [Osipova NA, Niauri DA, Gzgzyan AM. Renal ionoregulation function in incontinent women. Journal of Obstetrics and Women’s Diseases. 2016;65(2): 44-53. (In Russ.)]. doi: 10.17816/ JOWD65244-53.
- Пушкарь Д.Ю., Щавелева О.Б. Диагностика и результаты лечения смешанных форм недержания мочи у женщин // Урология. – 2005. – № 3. – С. 22–25. [Pushkar’ DJu, Shhaveleva OB. Diagnostika i rezul’taty lechenija smeshannyh form nederzhanija mochi u zhenshhin. Urologiia. 2005;(3):22-5. (In Russ.)]
- Тюзиков И.А., Греков Е.А., Апетов С.С., и др. Ноктурия: современные гендерные аспекты эпидемиологии, патогенеза и диагностики // Экспериментальная и клиническая урология. – 2013. – № 3. – С. 113–122. [Tjuzikov IA, Grekov EA, Apetov SS, et al. Nokturija: sovremennye gendernye aspekty jepidemiologii, patogeneza i diagnostiki. Jeksperi mental’naja i klinicheskaja urologija. 2013;(3):113-22. (In Russ.)]
- Тюзиков И.А., Калиниченко С.Ю., Ворслов Л.О., Тишова Ю.А. Дефицит вазопрессина как причина ноктурии и гормонально-метаболических нарушений у мужчин. Роль десмопрессина в их коррекции // Эффективная фармакотерапия. – 2015. – № 27. – С. 26–37.[Tyuzikov IA, Kalinchenko SYu, Vorslov LO, Tishova YuA. Vasopressin: non-classic effects and role in pathogenesis of age-associated diseases. Jeffektivnaja farmakoterapija. 2015;(27): 26-37. (In Russ.)]
- Aarab L, Siaume-Perez S, Chabardès D. Cell-specific coupling of PGE2 to different transduction pathways in arginine vasopressin- and glucagon-sensitive segments of the rat renal tubule. Br J Pharmacol. 1999;126(4):1041-9. doi: 10.1038/sj.bjp.0702390.
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. doi: 10.1002/nau.10052.
- Bissada NK. Urologic manifestations of drug therapy. Urol Clin Noth Am. 1988;15:725-36.
- Hampel C, Wienhold D, Benken N, et al. Prevalence and natural history of female incontinence. Eur Urol. 1997;32(suppl.23.12.):23-32.
- Han YK, Lee WK, Lee SH, et al. Effect of desmopressin with anticholinergics in female patients with overactive bladder. Korean J Urol. 2011;52(6):396-400. doi: 10.4111/kju.2011.52.6.396.
- Hilton P, Stanton SL. The use of Desmopressin in nocturnal urinary frequency in the female. Br J Urol. 1982; 54:252-5. doi: 10.1111/j.1464-410X.1982. tb06969.x.
- Jonas U. Introduction and conclusions. European Urology. 2005;4(1,suppl):1-4. doi: 10.1016/j.eursup.2004. 10.001.
- Jerez-Roig J, Santos MM, Souza DL, et al. Prevalence of urinary incontinence and associated factors in nursing home residents. Neurourol Urodyn. 2016;35(1):102-7. doi: 10.1002/nau.22675.
- Jeong JY, Kim SJ, Cho HJ, et al. Influence of type of nocturia and lower urinary tract symptoms on therapeutic outcome in women treated with desmopressin. Korean J Urol. 2013Feb;54(2):95-9. doi: 10.4111/kju.2013.54.2.95.
- van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardization of terminology in nocturia: report from the Standardization Subcommittee of the International Continence Society. Neurourol Urodyn. 2000;211: 79-83.
- Lee HW, Choo MS, Lee JG, et al. Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity. J Korean Med Sci. 2010Dec;25(12):1792-7. doi: 10.3346/jkms.2010.25.12.1792.
- Mun JH, Kim SO, Yu HS, et al. Effects of desmopressin for the treatment of nocturnal polyuria in elderly women: impact on related sleep quality. Can Urol Assoc J. 2015;9(11-12):E770-4. doi: 10.5489/ cuaj.3097.
- Nørgaard JP, Pedersen EB, Djurhuus JC. Diurnal anti-diuretic-hormone levels in enuretics. J Urol. 1985;134(5):1029-31.
- Rittig S, Knudsen UB, Nørgaard JP, et al. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256(4, pt 2):F664-71.
- Robinson D, Cardozo L, Akeson M, et al. Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int. 2004;93(7):996-1000. doi: 10,1111/j.1464-410X.2004.04768.x.
- Rose A, Thimme A, Halfar C, et al. Severity of urinary incontinence of nursing home residents correlates with malnutrition, dementia and loss of mobility. Urol Int. 2013;91(2):165-9. doi: 10.1159/000348344.
- Rouffignac С. Multihormonal regulation of nephron epithelia achieved through combinational mode. Am J Physiol. 1995;269(4):R739-R748.
- Sabolic I, Brown D. Water transport in renal tubule is mediated by aquaporins. J Clin Invest. 1994;72(9): 698-700. doi: 10.1007/BF00212993.
- Sellers DJ, Chapple CR, Chess-Williams R. Potential therapeutic targets for the treatment of the overactive bladder. World J Urol. 2001;19(5):307-31. doi: 10.1007/PL00007102.
- Turan C, Gurkan Zorlu C, Murat Ekin, et al. Urinary incontinence in women of reproductive age. Gynecol Obstet Invest. 1996;(41):132-4.
- Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs. 2000;10(1):65-83. doi: 10.1517/13543784.10.1.65.
- Kim JC, Park EY, Seo SI, et al. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006;175(5):1773-6. doi: 10.1016/S0022-5347(05)00992-4.
- Cho KJ, Kim HS, Koh JS, Kim JC. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics. Int Urogynecol J. 2013;24(2):325-30. doi: 10.1007/s00192-012-1854-4.
Supplementary files
